TEVJF — TEVA PHARMACEUTICAL INDUSTRIES LTD
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 818686 ·
Israel
Last close
$28.40
Market Cap
$33.07B
52W High
$37.00
52W Low
$28.40
ADV30
10
Next earnings
2026-07-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 3,981,000,000 | 1,972,000,000 | 759,000,000 | 369,000,000 | 40,040,000,000 | 3,741,000,000 | 31,808,000,000 |
| Dec 2025 | 4,711,000,000 | 2,656,000,000 | 1,269,000,000 | 480,000,000 | 40,748,000,000 | 3,556,000,000 | 32,834,000,000 |
| Sep 2025 | 4,480,000,000 | 2,304,000,000 | 1,075,000,000 | 433,000,000 | 39,856,000,000 | 2,203,000,000 | 32,602,000,000 |
| Jun 2025 | 4,176,000,000 | 2,102,000,000 | 899,000,000 | 282,000,000 | 40,131,000,000 | 2,161,000,000 | 33,297,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,714,000,000
Investing CF
$765,000,000
Financing CF
$-394,000,000
CapEx
$-542,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.14
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-13,394,000,000
Inventory
$3,176,000,000
Receivables
$3,393,000,000
ST Investments
—
EBIT TTM
$2,271,000,000
Pretax Income TTM
$1,366,000,000
Interest Exp TTM
$905,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$17,348,999,168
EBITDA
$5,002,999,808
Free Cash Flow
$2,611,375,104
Enterprise Value
$46,257,725,440
Total Cash
$3,740,999,936
Total Debt
$16,924,999,680
Shares Out
1,164,426,972
Trailing EPS
$1.34
Book Value
$7.07
ROE
21.6%
ROA
6.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 17,257,000,000 | 3,952,000,000 | 1,410,000,000 | 40,748,000,000 | 32,834,000,000 | — | 1,649,000,000 |
| Dec 2024 | 16,544,000,000 | 3,364,000,000 | -1,639,000,000 | 39,326,000,000 | 33,606,000,000 | — | 1,247,000,000 |
| Dec 2023 | 15,845,000,000 | 3,194,000,000 | -559,000,000 | 43,479,000,000 | 35,353,000,000 | — | 1,368,000,000 |
| Dec 2022 | 14,925,000,000 | 2,690,000,000 | -2,446,000,000 | 44,011,000,000 | 35,413,000,000 | — | 1,590,000,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZTS | Zoetis Inc. | $31.59B | $75.35 | — |
| ONC | BeOne Medicines Ltd. | $30.93B | $325.90 | — |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $35.88B | $30.81 | — |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $36.28B | $271.77 | — |
| BEIGF | BeOne Medicines Ltd. | $27.08B | $21.95 | — |
News headlines (Yahoo Finance, 1h cache)
Why Teva Pharmaceutical Stock Is a Buy Despite Trump Tariff Threat
2026-07-23 17:27 · Yahoo
Dr. Reddy's Laboratories Q1 Earnings Call Highlights
2026-07-22 17:06 · Yahoo
Hoka Expected to Drive First Quarter Earnings Results for Deckers, Analysts Say
2026-07-21 21:09 · Yahoo
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised
2026-07-15 14:50 · Yahoo
Teva Pharmaceutical Industries (TEVA) Could Be 21% Below Fair Value On Vitiligo Trial Progress
2026-07-14 04:31 · Yahoo
Deckers Brands Announces Conference Call to Review First Quarter Fiscal 2027 Earnings Results
2026-07-13 20:05 · Yahoo
Teva (TEVA) Stock Looks Discounted On Cash Flow Yet Fair On Earnings
2026-07-13 15:11 · Yahoo
Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?
2026-07-13 14:43 · Yahoo
Teva (TEVA) Reports Promising Vitiligo Trial Results And Moves Anti IL 15 Drug Forward
2026-07-13 12:07 · Yahoo
Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study
2026-07-12 22:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.